Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus

Psychopharmacology

Volumn 220, Issue 3, 2012, Pages 599-610

  Tanahashi, Shunske ^a   Yamamura, Satoshi ^a   Nakagawa, Masanori ^a   Motomura, Eishi ^a   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Carbamazepine; CRF; Dorsal raphe nucleus; Lamotrigine; Medial prefrontal cortex; Microdialysis; Serotonin

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; CARBAMAZEPINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; LAMOTRIGINE; PEPTIDE HORMONE ANTAGONIST; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MALE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; RESPONSE TIME; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; UPREGULATION;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICRODIALYSIS; MOOD DISORDERS; PREFRONTAL CORTEX; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEROTONIN; TRIAZINES;

EID: 84858450887     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2506-y     Document Type: Article

References (65)

1. Adell A, Celada P, Abellan MT, Artigas F (2002) Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev 39:154-180 (Pubitemid 35341097)
2. Ahmad S, Fowler LJ, Whitton PS (2004a) Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 142:136-142 (Pubitemid 38698202)
3. Ahmad S, Fowler LJ, Whitton PS (2004b) Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 1029:41-47 (Pubitemid 39463305)
4. Ahmad S, Fowler LJ, Whitton PS (2005a) Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 371:1-8 (Pubitemid 40379382)
5. Ahmad S, Fowler LJ, Whitton PS (2005b) Lamotrigine, carbamaze-pine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 63:141-149
6. Alexander SP, Mathie A, Peters JA (2009) Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158(Suppl 1):S1-254
7. Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P (2011) Lamotrigine: when and where does it act in affective disorders? A systematic review. J Psychopharmacol (in press)
8. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12 (Pubitemid 29044562)
9. Bale TL (2005) Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm Behav 48:1-10 (Pubitemid 40779285)
10. Behan DP, Grigoriadis DE, Lovenberg T, Chalmers D, Heinrichs S, Liaw C et al (1996) Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry 1:265-277 (Pubitemid 126441312)
11. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617-620 (Pubitemid 351705339)
12. Chen R, Lewis KA, Perrin MH, Vale WW (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90:8967-8971 (Pubitemid 23306432)
13. Chen C, Dagnino R Jr, De Souza EB, Grigoriadis DE, Huang CQ, Kim KI et al (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem 39:4358-4360 (Pubitemid 26359391)
14. Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G (2001) Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J Pharmacol Exp Ther 296:113-120 (Pubitemid 32015068)
15. Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN et al (2008) Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem 16:6379-6386 (Pubitemid 351783416)
16. El-Mallakh RS, Salem MR, Chopra A, Mickus GJ, Penagaluri P, Movva R (2010) A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects. Ann Clin Psychiatry 22:3-8
17. Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4-9
18. Gold PW, Wong ML, Chrousos GP, Licinio J (1996) Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Mol Psychiatry 1:257-264
19. Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM (2009) Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci 1179:120-143
20. Holsboer F, Ising M (2008) Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350-357
21. Imai H, Steindler DA, Kitai ST (1986) The organization of divergent axonal projections from the midbrain raphe nuclei in the rat. J Comp Neurol 243:363-380 (Pubitemid 16179241)
22. Ji G, Neugebauer V (2007) Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol 97:3893-3904 (Pubitemid 47080625)
23. Ji G, Neugebauer V (2008) Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J Neurophysiol 99:1201-1212 (Pubitemid 351419072)
24. Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA et al (2007) Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci 27:13329-13340 (Pubitemid 350220503)
25. Kawata Y, Okada M, Murakami T, Kamata A, Zhu G, Kaneko S (2001) Pharmacological discrimination between effects of carba-mazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release. Br J Pharmacol 133:557-567 (Pubitemid 32591922)
26. Ketter TA, Wang PW, Nowakowska C, Marsh WK (2004) New medication treatment options for bipolar disorders. Acta Psy-chiatr Scand Suppl:18-33
27. Kirby LG, Rice KC, Valentino RJ (2000) Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22:148-162 (Pubitemid 30016017)
28. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F et al (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin- releasing hormone receptor-2. Nat Genet 24:415-419 (Pubitemid 30187444)
29. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28:407-414
30. Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A (2002) The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol 136:896-904
31. Le Quellec A, Dupin S, Genissel P, Saivin S, Marchand B, Houin G (1995) Microdialysis probes calibration: gradient and tissue dependent changes in no net flux and reverse dialysis methods. J Pharmacol Toxicol Methods 33:11-16
32. Marrosu F, Fratta W, Carcangiu P, Giagheddu M, Gessa GL (1988) Localized epileptiform activity induced by murine CRF in rats. Epilepsia 29:369-373
33. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al (2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369:1000-1015 (Pubitemid 46436124)
34. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al (2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016-1026 (Pubitemid 46436125)
35. Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M (1979) Relationships between plasma concentrations of diphenyl-hydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 20:623-633 (Pubitemid 10215226)
36. Mattson R (2002) Antiepileptic drug monotherapy in adults. In: Levy RH MR, Meldrum BS, Perucca E (ed) Antiepileptic drugs, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 72-95
37. McLean MJ, Macdonald RL (1986) Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 238:727-738 (Pubitemid 16039621)
38. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR (2005) Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Psychopharmacology (Berl) 180:159-168 (Pubitemid 40897082)
39. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC (1998) Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46:547-551 (Pubitemid 28522118)
40. Muller MB, Wurst W (2004) Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med 10:409-415 (Pubitemid 39061143)
41. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S (2001) Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 134:507-520 (Pubitemid 32977895)
42. Okada M, Hirano T, Mizuno K, Chiba T, Kawata Y, Kiryu K et al (1997) Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res 28:143-153 (Pubitemid 27356291)
43. Okada M, Hirano T, Mizuno K, Kawata Y, Wada K, Murakami T et al (1998a) Effects of carbamazepine on hippocampal serotonergic system. Epilepsy Res 31:187-198 (Pubitemid 28370845)
44. Okada M, Wada K, Kiryu K, Kawata Y, Mizuno K, Kondo T et al (1998b) Effects of Ca2+ channel antagonists on striatal dopamine and DOPA release, studied by in vivo microdialysis. Br J Pharmacol 123:805-814 (Pubitemid 28085379)
45. Okada M, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T et al (1999) Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Eur J Neurosci 11:1-9 (Pubitemid 29012306)
46. Paxinos G, Watson C (1998) The rat brain. In Stereotoxic coordinates, 4th edn. Academic
47. Price ML, Lucki I (2001) Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. J Neurosci 21:2833-2841 (Pubitemid 32298224)
48. Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I (1998) Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18:492-502 (Pubitemid 28202356)
49. Southam E, Kirkby D, Higgins GA, Hagan RM (1998) Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 358:19-24 (Pubitemid 28464464)
50. Southam E, Pereira R, Stratton SC, Sargent R, Ford AJ, Butterfield LJ et al (2005) Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo. Eur J Pharmacol 519:237-245 (Pubitemid 41278544)
51. Tringali G, Aubry JM, Navarra P, Pozzoli G (2006) Lamotrigine inhibits basal and Na +-stimulated, but not Ca2 + -stimulated, release of corticotropin-releasing hormone from the rat hypothalamus. Psychopharmacology (Berl) 188:386-392 (Pubitemid 44387466)
52. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002) Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943:142-150 (Pubitemid 34671182)
53. Valentino RJ, Lucki I, Van Bockstaele E (2010) Corticotropin-releasing factor in the dorsal raphe nucleus: linking stress coping and addiction. Brain Res 1314:29-37
54. Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN (2000) Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol 130:242-248 (Pubitemid 30261033)
55. Xie X, Dale TJ, John VH, Cater HL, Peakman TC, Clare JJ (2001) Electrophysiological and pharmacological properties of the human brain type IIA Na+channel expressed in a stable mammalian cell line. Pflugers Arch 441:425-433 (Pubitemid 32128138)
56. Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S et al (2009a) Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res 84:172-186
57. Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S et al (2009b) Effects of quetiapine on mono-amine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl) 206:243-258
58. Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T et al (2009c) Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol 157:656-665
59. Yamamura S, Ohoyama K, Nagase H, Okada M (2009d) Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 57:322-331
60. Yamamura S, Saito H, Suzuki N, Kashimoto S, Hamaguchi T, Ohoyama K et al (2009e) Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors. Neurosci Lett 454:91-96
61. Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno S, Okada M (2011) Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions. Neuropharmacology 60:550-560
62. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C et al (2009) Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11:225-255
63. Yoshida S, Okada M, Zhu G, Kaneko S (2007) Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 52:1538-1546 (Pubitemid 46678087)
64. Zhu G, Okada M, Yoshida S, Ueno S, Mori F, Takahara T et al (2008) Rats harboring S284L Chrna4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype. J Neurosci 28:12465-12476
65. Zorrilla EP, Koob GF (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15:371-383